Pharmacotherapy relapse prevention in body dysmorphic disorder.
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Escitalopram (Primary)
- Indications Somatoform disorders
- Focus Therapeutic Use
- 08 Apr 2016 Primary endpoint of relapse of body dysmorphic disorder (BDD) symptoms (as Measured by the BDD-YBOCS) has been met, according to results published in the American Journal of Psychiatry.
- 08 Apr 2016 Results published in the American Journal of Psychiatry
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.